Sichuan, China

Xiaoquan Wu


 

 

Average Co-Inventor Count = 9.9

ph-index = 1


Company Filing History:


Years Active: 2023-2024

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):

Title: Innovator Xiaoquan Wu: Pioneering BRD4 Inhibitors for Cancer Treatment

Introduction

Xiaoquan Wu, an esteemed inventor based in Sichuan, China, has made significant contributions to the medical field with his innovative work on BRD4 inhibitors and their applications in cancer therapy. With a total of two patents to his name, Wu's research focuses on developing compounds that effectively combat prostate and breast cancer cells.

Latest Patents

Wu's latest patents include a compound of formula (I), which demonstrates a remarkable inhibitory effect on the proliferation of human prostate cancer cells (CWR22RV1) and breast cancer cells. This compound can be utilized independently as an antineoplastic agent or in conjunction with other drugs, such as androgen receptor inhibitors, to enhance its therapeutic efficacy against prostate cancer and breast cancer. Moreover, another patent details a BRD4 inhibitor that also exhibits significant inhibitory effects on prostate cancer cell proliferation, positioning itself as a promising drug for cancer treatment as well as for tackling autoimmune and inflammatory diseases.

Career Highlights

Currently, Wu is affiliated with Hinova Pharmaceuticals Inc., a company dedicated to innovative drug development. Throughout his career, he has focused on creating groundbreaking solutions that address pressing medical challenges, particularly in oncology. His dedication to research and development has positioned him at the forefront of cancer treatment innovations.

Collaborations

In his professional journey, Wu collaborates with talented colleagues such as Lei Fan and Kexin Xu. These partnerships foster an environment of shared expertise and innovative thinking, further advancing their collective goal of developing effective therapeutic agents.

Conclusion

Xiaoquan Wu's pioneering work in the realm of BRD4 inhibitors and cancer treatment showcases his commitment to improving patient outcomes in oncology. With continued research and collaboration within the pharmaceutical field, Wu's contributions have the potential to make a lasting impact on cancer therapies and treatment strategies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…